ClinicalTrials.gg
CompletedNCT02752412LIXILAN JP-LUpdated Jun 16, 2020

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

A Phase 3 interventional study of Insulin glargine/Lixisenatide (HOE901/AVE0010) and Insulin glargine U100 (HOE901) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 122 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
513
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
46th of 175
513 · median 253
Started
2016
with 7 others
Phase 3
60 of 176
1 open now
Registered
132nd of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 46th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2016, is one of 60 in phase 3, and was the 132nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to week 26 in patients with type 2 diabetes mellitus.

Secondary Objective:

To compare overall efficacy and safety of LixiLan to insulin glargine over 26 weeks in patients with type 2 diabetes mellitus.

Read the detailed description

The maximum study duration per patient will be approximately 41 weeks: an up to 14-week screening period (consisting of an up to 2-week screening phase and a 12-week run-in phase), a 26-week randomized treatment period, and a 3-day post-treatment safety follow-up period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year before the screening visit (V1).
  • Patient treated with a stable, once a day basal insulin regimen (ie, type of insulin and time/frequency of the injection), for at least 3 months before the screening visit.
  • The total daily basal insulin dose should be stable (± 20%) and \<15 U/day for at least 1 month before the screening visit.
  • Patient receiving 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months before the screening visit. The OADs can be 1 to 2 out of:
  • Metformin;
  • Sulfonylurea (SU);
  • Glinide;
  • Dipeptidyl-peptidase-4 (DPP-4) inhibitor;
  • Sodium glucose co-transporter 2 (SGLT2) inhibitor;
  • Alpha glucosidase inhibitor (alpha-GI).
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Age \<20 years at screening visit.
  • at screening visit \<7.5% or >9.5%.
  • Fasting plasma glucose (FPG) >180 mg/dL (10.0 mmol/L) at screening visit.
  • Pregnancy or lactation, women of with no effective method.
  • Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria in the 3 months before screening visit.
  • Previous use of insulin regimen other than basal insulin, eg, prandial or pre-mixed insulin.

Note: Short-term treatment (≤10 days) due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator.

  • Use of thiazolidinedione (TZD) within 6 months prior to screening visit.
  • History of discontinuation of a previous treatment with a glucagon-like peptide-1(GLP-1) receptor agonist due to safety/ tolerability issues or lack of efficacy.
  • Laboratory findings at the screening visit; including:
  • Amylase and/or lipase >3 times the (ULN) laboratory range;
  • (ALT) or aspartate aminotransferase (AST) >3 ULN;
  • Calcitonin ≥20 pg/mL (5.9 pmol/L);
  • Positive serum pregnancy test.
  • Any to metformin use according to local labeling.
  • History of to any GLP-1 receptor agonist or to metacresol.
  • Contraindication to use of insulin glargine or lixisenatide according to local labeling. History of hypersensitivity to insulin glargine or to any of the .
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (eg, multiple endocrine neoplasia syndromes).
  • History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has now been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy, stomach/gastric surgery.
  • Exclusion criteria for randomization at the end of the run-in phase:
  • HbA1c \<7.5% or >9.5% at visit 6 (Week -1).
  • Mean fasting self monitored plasma glucose (SMPG) >160 mg/dL (8.9 mmol/L), calculated from all available (minimum of 4 self-measurements) values during the 7 days prior to randomization.

Note:fasting SMPG on the day of randomization can be included if assessed before randomization.

  • Average insulin glargine daily dose ≥15 U/day or \<5U/day calculated for the last 3 days before Visit 7.
  • Metformin total daily dose \<750 mg/day.
  • Amylase and/or lipase >3 ULN at Visit 6 (Week -1).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
513 participants (actual)

Study arms

  • Experimental
    LixiLan

    LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Metformin will be continued.

    Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010) · Drug: Metformin

  • Active comparator
    insulin glargine

    Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted. Metformin will be continued.

    Drug: Insulin glargine U100 (HOE901) · Drug: Metformin

Interventions

  • DrugInsulin glargine/Lixisenatide (HOE901/AVE0010)

    Drug pages: Insulin Glargine · Lixisenatide

    Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: LixiLan

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Lantus

  • Pharmaceutical form: tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Percentage of patients reaching HbA1c <7% or ≤6.5%

    Time frame: 26 weeks

  2. Change from baseline in 2-hour postprandial plasma glucose (PPG) during standardized meal test

    Time frame: Baseline, 26 weeks

  3. Change from baseline in blood glucose excursion during standardized meal test

    Time frame: Baseline, 26 weeks

  4. Change from baseline in 7-point self-monitoring plasma glucose (SMPG) profiles (each time point and average daily value)

    Time frame: Baseline, 26 weeks

  5. Change from baseline in body weight

    Time frame: Baseline, 26 weeks

  6. Change from baseline in FPG

    Time frame: Baseline, 26 weeks

  7. Change from baseline in daily dose of insulin glargine

    Time frame: Baseline, 26 weeks

  8. Percentage of patients reaching HbA1c <7% with no body weight gain

    Time frame: 26 weeks

  9. Percentage of patients reaching HbA1c <7% with no body weight gain and with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia

    Time frame: 26 weeks

  10. Percentage of patients reaching HbA1c <7% with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia

    Time frame: 26 weeks

  11. Percentage of patients requiring a rescue therapy

    Time frame: 26 weeks

  12. Number of hypoglycemic events

    Time frame: 26 weeks

  13. Number of adverse events

    Time frame: 26 weeks

  14. Measurement of anti-lixisenatide antibodies from baseline

    Time frame: Baseline, 26 weeks

  15. Measurement of anti-insulin antibodies from baseline

    Time frame: Baseline, 26 weeks

07

Study locations

122 sites
  • Investigational Site Number 392002
    Adachi-Ku, Japan
  • Investigational Site Number 392132
    Annaka-Shi, Japan
  • Investigational Site Number 392009
    Arakawa-Ku, Japan
  • Investigational Site Number 392152
    Asahikawa-Shi, Japan
  • Investigational Site Number 392025
    Atsugi-Shi, Japan
  • Investigational Site Number 392024
    Chiba-Shi, Japan
  • Investigational Site Number 392151
    Chiba-Shi, Japan
  • Investigational Site Number 392011
    Chigasaki-Shi, Japan
  • Investigational Site Number 392013
    Chiyoda-Ku, Japan
  • Investigational Site Number 392052
    Chiyoda-Ku, Japan
  • Investigational Site Number 392003
    Chuo-Ku, Japan
  • Investigational Site Number 392017
    Chuo-Ku, Japan
  • Investigational Site Number 392055
    Chuo-Ku, Japan
  • Investigational Site Number 392008
    Fujimi-Shi, Japan
  • Investigational Site Number 392143
    Fujisawa-Shi, Japan
  • Investigational Site Number 392094
    Fukuoka-Shi, Japan
  • Investigational Site Number 392147
    Fukuoka-Shi, Japan
  • Investigational Site Number 392100
    Gifu-Shi, Japan
  • Investigational Site Number 392059
    Hachioji-Shi, Japan
  • Investigational Site Number 392048
    Hamamatsu-Shi, Japan
  • Investigational Site Number 392102
    Hamamatsu-Shi, Japan
  • Investigational Site Number 392123
    Higashiosaka-Shi, Japan
  • Investigational Site Number 392135
    Higashiosaka-Shi, Japan
  • Investigational Site Number 392079
    Hiki-Gun, Japan
  • Investigational Site Number 392141
    Himeji-Shi, Japan
  • Investigational Site Number 392057
    Iruma-Shi, Japan
  • Investigational Site Number 392022
    Ise-Shi, Japan
  • Investigational Site Number 392020
    Izumisano-Shi, Japan
  • Investigational Site Number 392036
    Kamakura-Shi, Japan
  • Investigational Site Number 392136
    Kamogawa-Shi, Japan
  • Investigational Site Number 392066
    Kashiwa-Shi, Japan
  • Investigational Site Number 392045
    Kashiwara-Shi, Japan
  • Investigational Site Number 392006
    Kasugai-Shi, Japan
  • Investigational Site Number 392149
    Kasugai-Shi, Japan
  • Investigational Site Number 392053
    Kawagoe-Shi, Japan
  • Investigational Site Number 392065
    Kawagoe-Shi, Japan
  • Investigational Site Number 392007
    Kawaguchi-Shi, Japan
  • Investigational Site Number 392062
    Kawaguchi-Shi, Japan
  • Investigational Site Number 392090
    Kawaguchi-Shi, Japan
  • Investigational Site Number 392077
    Kawasaki-Shi, Japan
  • Investigational Site Number 392082
    Kawasaki-Shi, Japan
  • Investigational Site Number 392142
    Kawasaki-Shi, Japan
  • Investigational Site Number 392010
    Kisarazu-Shi, Japan
  • Investigational Site Number 392016
    Kisarazu-Shi, Japan
  • Investigational Site Number 392031
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392068
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392041
    Kitakyusyu-Shi, Japan
  • Investigational Site Number 392086
    Kobe-Shi, Japan
  • Investigational Site Number 392044
    Koga-Shi, Japan
  • Investigational Site Number 392001
    Koriyama-Shi, Japan
  • Investigational Site Number 392028
    Kumamoto-Shi, Japan
  • Investigational Site Number 392092
    Kumamoto-Shi, Japan
  • Investigational Site Number 392108
    Kumamoto-Shi, Japan
  • Investigational Site Number 392116
    Kumamoto-Shi, Japan
  • Investigational Site Number 392099
    Kushiro-Shi, Japan
  • Investigational Site Number 392049
    Kyoto-Shi, Japan
  • Investigational Site Number 392107
    Kyoto-Shi, Japan
  • Investigational Site Number 392088
    Maebashi-Shi, Japan
  • Investigational Site Number 392158
    Maebashi-Shi, Japan
  • Investigational Site Number 392121
    Matsuyama-Shi, Japan
  • Investigational Site Number 392122
    Minato-Ku, Japan
  • Investigational Site Number 392076
    Misato-Shi, Japan
  • Investigational Site Number 392014
    Mitaka-Shi, Japan
  • Investigational Site Number 392042
    Mito-Shi, Japan
  • Investigational Site Number 392043
    Mito-Shi, Japan
  • Investigational Site Number 392078
    Mito-Shi, Japan
  • Investigational Site Number 392046
    Miyazaki-Shi, Japan
  • Investigational Site Number 392026
    Nagoya-Shi, Japan
  • Investigational Site Number 392101
    Nagoya-Shi, Japan
  • Investigational Site Number 392128
    Nagoya-Shi, Japan
  • Investigational Site Number 392131
    Nagoya-Shi, Japan
  • Investigational Site Number 392134
    Nagoya-Shi, Japan
  • Investigational Site Number 392137
    Nagoya-Shi, Japan
  • Investigational Site Number 392140
    Nagoya-Shi, Japan
  • Investigational Site Number 392154
    Naka-Shi, Japan
  • Investigational Site Number 392050
    Niihama-Shi, Japan
  • Investigational Site Number 392159
    Obihiro-Shi, Japan
  • Investigational Site Number 392145
    Ogaki-Shi, Japan
  • Investigational Site Number 392153
    Oita-Shi, Japan
  • Investigational Site Number 392005
    Okawa-Shi, Japan
  • Investigational Site Number 392071
    Okayama-Shi, Japan
  • Investigational Site Number 392080
    Okayama-Shi, Japan
  • Investigational Site Number 392095
    Onga-Gun, Japan
  • Investigational Site Number 392105
    Osaka-Shi, Japan
  • Investigational Site Number 392117
    Osaka-Shi, Japan
  • Investigational Site Number 392144
    Osaka-Shi, Japan
  • Investigational Site Number 392125
    Osaki-Shi, Japan
  • Investigational Site Number 392120
    Ota-Ku, Japan
  • Investigational Site Number 392157
    Ota-Shi, Japan
  • Investigational Site Number 392040
    Oyama-Shi, Japan
  • Investigational Site Number 392038
    Sagamihara-Shi, Japan
  • Investigational Site Number 392069
    Saijo-Shi, Japan
  • Investigational Site Number 392030
    Saitama-Shi, Japan
  • Investigational Site Number 392058
    Saitama-Shi, Japan
  • Investigational Site Number 392074
    Sanda-Shi, Japan
  • Investigational Site Number 392047
    Sapporo-Shi, Japan
  • Investigational Site Number 392106
    Sapporo-Shi, Japan
  • Investigational Site Number 392097
    Sasebo-Shi, Japan
  • Investigational Site Number 392015
    Satsumasendai-Shi, Japan
  • Investigational Site Number 392004
    Sendai-Shi, Japan

Showing the first 100 of 122 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Kaneto H, Takami A, Spranger R, Amano A, Watanabe D, Niemoeller E. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial. Diabetes Obes Metab. 2020 Sep;22 Suppl 4:3-13. doi: 10.1111/dom.14005. PubMed 32072742 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Oct 2018, 28 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2016
First posted
Apr 27, 2016
StartActual
May 17, 2016
Primary completionActual
Oct 4, 2018
CompletionActual
Oct 4, 2018
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02752412
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 27, 2016
Start date
May 17, 2016
Primary completion
Oct 4, 2018
Completion
Oct 4, 2018
Last update
Jun 16, 2020

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Lixisenatide

Start the discussion